FDA approves Lumvoa for thyroid eye disease

The U.S. Food and Drug Administration has granted approval to Lumvoa (veligrotug‑vvze) for the treatment of thyroid eye disease (TED). The approval was issued to Viridian Therapeutics, marking the company’s first FDA‑approved product for this autoimmune condition that can cause inflammation, bulging, and vision impairment in the eyes of patients with thyroid disorders.

Lumvoa is the first therapy specifically indicated for TED, offering a targeted option for patients who have limited alternatives beyond corticosteroids and surgical interventions. The FDA’s decision follows a review of clinical data demonstrating the drug’s efficacy in reducing disease activity and improving ocular outcomes. Viridian Therapeutics plans to launch the medication later this year, providing a new therapeutic avenue for individuals affected by thyroid eye disease.